Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Zhaozhen WuHaitao TaoSujie ZhangXiao WangJunxun MaRuixin LiZhefeng LiuJinliang WangPengfei CuiShixue ChenHuang DiZiwei HuangXuan ZhengYi HuPublished in: Cancer immunology, immunotherapy : CII (2021)
PARPi/anti-PD-1 is an effective and tolerable method for patients with advanced solid tumors, and BRCA1/2 is a potential biomarker.